Literature DB >> 24931656

Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone.

Yu-Ting Wang1, Nan-Ying Chiu, Shaw-Hwa Jou, Yen Kuang Yang, I Hui Lee, Ching-Cheng Wang, Kao Ching Chen, Yi-Cheng Liao.   

Abstract

Objectives. The aims of this 13-week study were to examine the efficacy and safety of amisulpride, and effects on cognitive function in patients with schizophrenia after they switched from risperidone. Methods. Twenty-three patients with schizophrenia whose antipsychotic was switched from risperidone to amisulpride were recruited. The efficacy, safety, and cognitive function were assessed. Results. Significant improvements were noted in the PANSS, CGI-S, and MADRS. The prolactin level, but not any of the remaining laboratory variables, increased significantly. The cognitive function improved significantly, particularly in memory subtests. Conclusions. Switching antipsychotic from risperidone to amisulpride in schizophrenia might have significantly improved not only the efficacy, but also various domains of cognitive function. However, hyperprolactinemia existed and was sometimes even worse.

Entities:  

Keywords:  Amisulpride; cognitive function; hyperprolactinemia

Year:  2008        PMID: 24931656     DOI: 10.1080/13651500701805727

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  4 in total

1.  The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study.

Authors:  Ying Liang; Xin Yu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-21       Impact factor: 2.570

2.  Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial.

Authors:  Ming-Huan Zhu; Zhen-Jing Liu; Qiong-Yue Hu; Jia-Yu Yang; Ying Jin; Na Zhu; Ying Huang; Dian-Hong Shi; Min-Jia Liu; Hong-Yang Tan; Lei Zhao; Qin-Yu Lv; Zheng-Hui Yi; Feng-Chun Wu; Ze-Zhi Li
Journal:  Mil Med Res       Date:  2022-10-18

3.  Update on the management of symptoms in schizophrenia: focus on amisulpride.

Authors:  Ann M Mortimer
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

4.  The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study.

Authors:  Ying Liang; Changan Cao; Cheng Zhu; Chuanyue Wang; Congpei Zhang; Fang Dong; Fude Yang; Hong Deng; Jingjie Yu; Jisheng Tang; Lei Su; Limin Xin; Ling Hong; Minglong Gao; Muni Tang; Shiping Xie; Shuiping Lu; Tiebang Liu; Xiaojin Xu; Xijin Wang; Xuanzi Li; Xueyi Wang; Yi Li; Yong Zhang; Zhiyu Chen; Xin Yu
Journal:  Asia Pac Psychiatry       Date:  2016-03-28       Impact factor: 2.538

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.